Insight Pharmaceuticals recalls nasal spray over bacteria concerns

Insight Pharmaceuticals in Langhorne, Pennsylvania has voluntarily recalled one lot, or 34,092 bottles, of its Nostrilla Nasal Decongestant nasal spray, over concerns it may contain the bacteria Burkholderia cepacia, according to a statement from the company posted on the Food and Drug Administration’s website.

The bacteria could cause serious infection in individuals with a compromised immune system or chronic lung condition such as cystic fibrosis.

The recall was spurred by internal investigations that indicated the potential presence of a microbial contaminant that exceeds the product specifications.

Gary R. Downing, CEO of Insight Pharmaceuticals, said: ’Through our standard testing procedures and protocols, we discovered the potential presence of a bacterial contaminant in one lot of Nostrilla, and reported it to the FDA.”

Nostrilla Nasal Decongestant is distributed through retail outlets and pharmacies. No illnesses have been reported to date in connection with the problem, the company said.